- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic HER2-positive breast cancer after prior HER2-directed treatment
- Meeting Date: May 2026
- Public Summary Document (PSD) November 2025 – May 2026 PBAC Meetings - (PDF 1.2MB)
- Public Summary Document (PSD) November 2025 – May 2026 PBAC Meetings - (Word 448.2KB)
Tucatinib – November 2025 – May 2026
Tucatinib: Tablet 50 mg Tablet 150mg; Tukysa®
Last updated
14 September 2026